American Journal of Kidney Diseases
Volume 56, Issue 2 , Pages 189-218 , August 2010

KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients

  • Margaret Bia, MD

      Affiliations

    • Yale School of Medicine, New Haven, CT
    • Corresponding Author InformationAddress correspondence to Margaret Bia, MD, Section of Nephrology, Department of Internal Medicine, Yale School of Medicine, PO Box 208029, New Haven, CT 06520-8029
    • ,
  • Deborah B. Adey, MD

      Affiliations

    • University of Vermont/Fletcher Allen Health Care, Burlington, VT
    • ,
  • Roy D. Bloom, MD

      Affiliations

    • Hospital of the University of Pennsylvania, Philadelphia, PA
    • ,
  • Laurence Chan, MD

      Affiliations

    • University of Colorado Denver, Aurora, CO
    • ,
  • Sanjay Kulkarni, MD

      Affiliations

    • Yale School of Medicine, New Haven, CT
    • ,
  • Steven Tomlanovich, MD

      Affiliations

    • University of California, San Francisco, CA

References 

  1. McCullough KP, Keith DS, Meyer KH, et al. Kidney and pancreas transplant in the United States, 1998-2007: access for patients with diabetes and end stage renal disease. Am J Transplant. 2009;9:894–906
  2. Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004;66:1310–1414
  3. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):S19–S20
  4. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;109:S1–S99
  5. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–S113
  6. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant. 2007;7:1359–1375
  7. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–2575
  8. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony Study: observational results 3 years after transplantation. Am J Transplant. 2009;9:1876–1885
  9. Egbuna OI, Davis R, Chudinski R, et al. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation. Transplantation. 2009;88:684–692
  10. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009;5:1115–1123
  11. Schold JD, Kaplan B. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. Am J Transplant. 2009;9:2067–2074
  12. Gaston RS, Kaplan B, Shah T, et al. Fixed or controlled-dose mycophenolate mofetil with standard or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009;9:1607–1619
  13. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant. 2007;7:2538–2545
  14. Chang AT, Platt JC. The role of antibodies in transplantation. Transpl Rev. 2009;23:191–198
  15. Abbud-Filho M, Adams PL, Alberú J, et al. A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation. 2007;83(8 suppl):S1–S22
  16. Israni AK, Snyder JJ, Skeans MA, Tuomari AV, Maclean JR, Kasiske BL. Who is caring for kidney transplant patients? (Variation by region, transplant center, and patient characteristics). Am J Nephrol. 2009;30(5):430–439
  17. Lee PC, Zhu L, Terasaki P, Everly MJ. HLA specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation. 2009;88:568–574
  18. Everly MJ, Terasaki PI. Monitoring and treating posttransplant human leukocyte antigen antibodies. Hum Immunol. 2009;70:655–659
  19. Birnbaum LM, Lipman M, Paraskevas S, et al. Management of chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol. 2009;4:860–865
  20. Levey AS, Eckardt K-U, Tsukamoto T, et al. Definition and classification of Chronic Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100
  21. Jiménez Alvaro S, Marcén R, Teruel JL, et al. Management of chronic kidney disease after renal transplantation: is it different from nontransplant patients?. Transplant Proc. 2009;41:2409–2411
  22. Burgos FJ, Pascual J, Marcen R, et al. The role of imaging techniques in renal transplantation. World J Urol. 2004;22:399–404
  23. Hergesell O, Felten H, Andrassy K, et al. Safety of ultrasound guided percutaneous renal biopsy—retrospective analysis of 1090 consecutive cases. Nephrol Dial Transplant. 1998;13:975–977
  24. Mengel M, Chapman JR, Cosio FG, et al. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am J Transplant. 2007;7:512–517
  25. Reeve J, Einecke G, Mangel M, et al. : Diagnosing rejection in renal transplants: a comparison of molecular- and histolopathology-based approaches. Am J Transplant. 2009;9:1802–1810
  26. Bunnag S, Einecke G, Reeve J, et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol. 2009;20:1149–1160
  27. Saint-Mezard P, Berthier CC, Zhang H, et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transplant Int. 2009;3:293–302
  28. Golgert WA, Appel GB, Hariharan S. Recurrent glomerulonephritis after renal transplantation: an unsolved problem. Clin J Am Soc Nephrol. 2008;3:800–807
  29. Ghiggeri GM, Carraro M, Vincenti F. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant. 2004;19:1036–1040
  30. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant. 2006;6:2535–2542
  31. Little MA, Dupont P, Campbell E, et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 2006;69:504–511
  32. Fine RN, Becker Y, De Geest S, et al. Nonadherence consensus conference summary report. Am J Transplant. 2009;9:35–41
  33. Morrissey PE, Flynn ML, Lin S. Medication noncompliance and its implications in transplant recipients. Drugs. 2007;67:1463–1481
  34. Vlaminck H, Maes B, Evers G, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant. 2004;4:1509–1513
  35. AST Infectious Diseases Guidelines 2nd Edition. Am J Transplant. 2009;9(suppl 4):S1–S281
  36. Akalin E, Ames S, Sehgal V, Murphy B, Bromberg J. Safety of using hepatitis B core antibody or surface antigen-positive donors in kidney or pancreas transplantation. Clin Transplant. 2005;19:364–366
  37. Duchini A, Goss J, Karpen S, Pockros P. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev. 2003;16(3):357–364
  38. A randomized, placebo-controlled, dose-escalation study to assess the safety and effect of cidofivir in renal transplant recipients with BK virus nephropathy. NCT001384424. Clinical Trials.Gov. Accessed May 17, 2010.
  39. A multicenter, randomized, double-blind, placebo-controlled, multiple dose study of the safety, tolerability and population pharmacokinetics of CMX001 in post-transplant patients with BK virus viuria. NCT00793598. ClinicalTrials.Gov. Accessed May 17, 2010
  40. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8(5):975–983
  41. Weinberg A, Hodges TN, Li S, et al. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol. 2000;38:768–772
  42. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy (Collaborative Study Group). Ann Intern Med. 1996;125(8):634–639
  43. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8:355–365
  44. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest. 2009;136(1):198–204
  45. Kobashi Y, Mouri K, Obase Y, et al. Clinical evaluation of Quantiferon TB-2G test for immunocompromised patients. Eur Respir J. 2007;30:945–950
  46. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–185
  47. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3:590–598
  48. Nam JH, Mun JI, Kim SI, et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation. 2001;71:1417–1423
  49. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  50. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant. 2004;4:1675–1683
  51. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67:2415–2421
  52. Armstrong KA, Prins JB, Beller EM, et al. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients?. Clin J Am Soc Nephrol. 2006;1:100–108
  53. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 208;358:2545-2559.
  54. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes (Effects of intensive glucose lowering in type 2 diabetes). N Engl J Med. 2008;358:2560–2572
  55. National Kidney Foundation. KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis. 2004;43(suppl 1):S1–S290
  56. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  57. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889–899
  58. Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol. 2006;17:3257–3262
  59. Arthur JM, Shamim S. Interaction of cyclosporine and FK506 with diuretics in transplant patients. Kidney Int. 2000;58:325–330
  60. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4:13–53
  61. Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant. 2005;5:2236–2243
  62. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564–577
  63. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(suppl 3):S112–S119
  64. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003;75:1291–1295
  65. Gaston RS, Kasiske BL, Fieberg AM, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant. 2009;9:1811–1815
  66. Ulrich C, Jurgensen HS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161(suppl 3):78–84
  67. Mahe E, Morelon E, Fermanian J, et al. Renal-transplant recipients and sun protection. Transplantation. 2004;78:741–744
  68. Ismail F, Mitchell D, Casabone A, et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photo protection and levels of skin cancer awareness. Br J Dermatol. 2008;155(5):916–925
  69. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581–589
  70. Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999;94:2224–2229
  71. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67
  72. Stallone G, Infante B, Pontrelli P, et al. ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin. Am J Transplant. 2009;9(3):558–586
  73. Duman S, Toz H, Asci G, et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant. 2002;17:892–896
  74. Rojas E, Carlini R, Clesca P, et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int. 2003;63:1915–1923
  75. Stavroulopoulos A, Cassidy MJD, Porter CJ, Hosking DJ, Roe SD. Vitamin D status in renal transplant patients. Am J Transplant. 2007;7:2546–2552
  76. Palmer SC, Strippoli G, McGregor D. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005;45:638–649
  77. Coco M, Glicklich D, Fuagere MC, et al. Prevention of bone loss in renal transplant recipients: a prospective randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14:2669–2676
  78. Farmer CKT, Hampson G, Abbs IC. Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant. 2006;6:2929–2936
  79. van den Ham E, Kooman JP, van Hoof CMJP. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transplant Int. 2003;16:82–87
  80. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetics and females after renal transplantation. Transplantation. 1999;67:1218–1222
  81. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999;14:456–463
  82. Chadban SJ, Baines L, Polkinghorne K, et al. Anemia after kidney transplantation is not completely explained by reduced kidney function. Am J Kidney Dis. 2007;49:301–309
  83. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S1–S146
  84. Vimalachandra D, Craig JC, Cowell CT, et al. Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials. J Pediatr. 2001;39:560–567
  85. Tsujimura A, Matsumiya K, Tsuboniwa N, et al. Effect of renal transplantation on sexual function. Arch Androl. 2002;48:467–474
  86. Raiz L, Davies EA, Ferguson RM. Sexual functioning following renal transplantation. Health Soc Work. 2003;28:264–272
  87. McKay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant. 2005;5:1592–1599
  88. GLOBOCAN 2002. International Agency for Research on Cancer, Cancer Mondial; 2002;
  89. United States Cancer Statistics: 1999-2005 incidence and mortality web-based report (U.S. Cancer Statistics Working Group, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute). (vol 2009) Atlanta, GA: U.S. Cancer Statistics Working Group, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009;

 Originally published online as doi:10.1053/j.ajkd.2010.04.010 on July 2, 2010.

 Reprint requests to Kerry Willis, PhD, National Kidney Foundation, 30 E 33rd St, New York, NY 10016. E-mail: kerryw@kidney.org

PII: S0272-6386(10)00802-4

doi: 10.1053/j.ajkd.2010.04.010

American Journal of Kidney Diseases
Volume 56, Issue 2 , Pages 189-218 , August 2010

Article Tools

* Image Usage & Resolution